Association between exposure to GLP-1 receptor agonists and risk of suicide-related and self-harm-related events

Study type

• Study type:
  Non-interventional study

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Name of medicine, other:
  GLP-1 receptor agonists
• Medical condition to be studied:
  Suicidal ideation

  Self-injurious ideation

  Suicide attempt

  Completed suicide
• Additional medical condition(s):
  Self-injury/self-harm

Population studied

• Short description of the study population:
  The population eligible for the study will consist of patients: ; - registered with a GP-practice covered by IQVIA™ Medical research data (IMRD), ; - who initiated treatment with GLP-1 receptor agonists or SGLT-2 inhibitors (new users) during the study period, ; - who had not used GLP-1 receptor agonists or SGLT-2 inhibitors before index-date (i.e., date of index treatment initiation and the start of follow-up in the study), ; - with at least one year (365 days) of recorded medical history prior to index-date, ; - with at least one diagnosis of T2DM before index-date, ; - with no history of suicide-related or self-harm-related events prior to index-date, ; - who have been treated with biguanides (e.g., metformin, which is considered first-line antidiabetic treatment according to NICE guidelines (NICE, 2022)) before index-date. ; ; No exclusion will be applied according to age.
• Age groups:
  All

Study design details

• Main study objective:
  Is the use of GLP-1 receptor agonists associated with an increased risk of suicide-related and self-harm-related events when compared to patients who are prescribed SGLT-2 inhibitors among T2DM patients?

Documents

Study report

Final study report_Suicidal ideation and GLP1.pdf